First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Tony Mok et al.|New England Journal of Medicine|2018Cited by 3.5k
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony Mok, Makoto Nishio et al.|The Lancet Respiratory Medicine|2019Cited by 937
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Geoffrey R. Oxnard et al.|New England Journal of Medicine|2020Cited by 835
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V. Liu, Leora Horn, Martin Reck et al.|Journal of Clinical Oncology|2021Cited by 818
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227Julie R. Brahmer, Suresh S. Ramalingam, Jong-Seok Lee et al.|Journal of Clinical Oncology|2022Cited by 375